Tisento Therapeutics has initiated its global Phase 2b PRIZM study, evaluating zagociguat for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.